[{"id":"b6b2754e-5306-4023-a3e5-75d3f7fe5848","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620134","created_at":"2022-11-17T14:57:00.380Z","updated_at":"2024-07-02T16:35:08.649Z","phase":"Phase 1/2","brief_title":"Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer","source_id_and_acronym":"NCT05620134","lead_sponsor":"Salubris Biotherapeutics Inc","biomarkers":" HER-2 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["HER-2 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SAL008"],"overall_status":"Recruiting","enrollment":" Enrollment 263","initiation":"Initiation: 10/17/2022","start_date":" 10/17/2022","primary_txt":" Primary completion: 10/17/2025","primary_completion_date":" 10/17/2025","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2024-04-19"}]